Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2327 in Anxious Major Depressive Disorder
NCT00759395Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing AZD2327 with Placebo (2 arms). Primary endpoints: Hamilton Rating Scale for Depression Total Score at 4 weeks and Hamilton Rating Scale for Anxiety Total Score at 4 weeks. Started Jan 2009; status: completed.
02
Drugs
AZD-2327
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00759395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759395.